Marks First Purchase of MRIdian Linac in Europe following CE Mark Approval
January 19, 2017
CLEVELAND, January 19, 2017 — ViewRay, Inc. (Nasdaq: VRAY)announced today that the German Research Foundation (DFG), a federal institution supporting research in Germany, has purchased a MRIdian Linac for installation and patient treatments at the University Clinic Heidelberg as part of its initiative for MRI-based radiation therapy.
The MRIdian Linac program will be headed by Medical Director and Professor Jürgen Debus, M.D., Ph.D., who also heads radiation oncology at the German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion Center (HIT) and the Marbug Heavy Ion Center (MIT). The University Clinic Heidelberg will be an important MRIdian research partner, helping to explore a wide array of topics including improved dose delivery through MRI-guidance and various clinical studies.
“We are proud to be the first to acquire MRIdian Linac within Europe and to extend the benefits of MRI-guided radiation therapy to our patients,” said Professor Debus. “The MRIdian Linac significantly improves our ability to visualize the tumor and will allow us to spare as much healthy tissue as possible while ensuring we deliver only the precise amount of radiation prescribed.”
The MRIdian Linac is the first, and currently the only, MRI-guided linear accelerator available for clinical use in Europe. DFG’s purchase of the MRIdian Linac marks the first in Europe since ViewRay received its CE Mark approval in September. The MRIdian Linac is a next-generation linear accelerator-based MRI-guided radiation therapy system. Using the MRIdian Linac system, clinicians can see soft tissue, and visualize and adjust the dose in real-time.
“MRIdian Linac is an important advance in how we plan and treat with radiation therapy, offering us the opportunity to deliver real-time adaptive therapy,” said Professor Markus Alber, Ph.D., professor for radiation physics research at the University Clinic Heidelberg. “We selected MRIdian Linac specifically for its exceptional beam quality and its fully integrated treatment planning and delivery workflow.”
“We’re pleased to see the first MRIdian Linac clinical program in Europe take shape with such a prestigious institution,” said Chris A. Raanes, president and chief executive officer of ViewRay. “We believe this is an important milestone in establishing MRIdian as a standard of care in radiation oncology and solidifies our clinical leadership role in the MRI-guided radiation therapy field.”
ViewRay®, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
In the United States, ViewRay has submitted a 510(k) application for the MRIdian Linac, the company’s MR Linac technology. Therefore, the MRIdian Linac is not available for sale or distribution in the United States except for non-clinical research use. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the head of the MRIdian Linac program at the University Clinic Heidelberg, the University Clinic Heidelberg’s research efforts using MRIdian, the demand for MRI-guided radiation therapy in Germany, the benefits of the MRIdian Linac for physicians and patients in Germany, the expected reception of the MRIdian Linac in Germany and the receipt by the University Clinic Heidelberg of its MRIdian Linac. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.